PYC Therapeutics (PYC) Q2 2025 earnings summary

Executive summary

• Four pipeline assets are advancing, with three in human trials and one preclinical candidate progressing toward 2026 human studies, and a focus on achieving key milestones in the next 24 months.

• Achieved key clinical milestones in PKD, RP11, and ADOA programs, including dosing and proof-of-concept data, with multiple human efficacy readouts expected within the next 12 months.

• Provided detailed updates on each pipeline program, including year-to-date progress and 2025 objectives, and outlined platform implications of near-term milestones.

• Industry environment remains challenging, but RNA therapeutics is a high-momentum subsector with strong commercial interest.

• Raised $146 million in Q1 2025, extending cash runway to over $200 million into CY27.

Financial highlights

• Ended Q2 2025 with $153 million in cash and cash equivalents, with net cash used in operating activities of $17.7 million for the quarter.

• Current capital reserves are sufficient to take the lead asset (RP11) through registrational studies, estimated at $60 million.

• Received $17.3 million in government grants and tax incentives during the quarter.

• Raised $37.1 million from equity issuance in Q2 2025, with $4 million in related transaction costs.

• R&D rebate of $20 million expected in H2 2025.

Outlook and guidance

• All pipeline programs are expected to deliver critical data in 2025, including clinical proof-of-concept and human safety results.

• Human trials for PMS program anticipated to begin in 2026 following completion of IND-enabling studies.

• Open label extension for RP11 to provide 24-month data, with increased dosing and potential for pivotal trial initiation.

• Polycystic kidney disease program to enter repeat dosing in Q4, with key data expected late this year or early next.

• Cash runway projected to extend into CY27, supported by recent capital raise and anticipated R&D rebate.